Athenex Announces MAA Validation Of Oral Paclitaxel For Review - Quick Facts

Athenex, Inc. (ATNX) said its Marketing Authorization Application for oral Paclitaxel for the treatment of advanced breast cancer has been validated by the United Kingdom's Medicines and Healthcare products Regulatory Agency for review. A single pivotal phase III study of oral Paclitaxel was the basis of the Marketing Authorization Application.

The company noted that the application qualifies for a 150 day assessment by which a decision on approvability of the product will be provided.

Shares of Athenex were up 4% in pre-market trade on Monday.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT